Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension: insights from a single-centre study

被引：0
|
作者：
Tokgoz, H. C. [1 ]
Kultursay, B. [1 ]
Tanyeri, S. [2 ]
Hakgor, A. [3 ]
Keskin, B. [2 ]
Bulus, C. [1 ]
Sekban, A. [1 ]
Sirma, D. [1 ]
Karagoz, A. [1 ]
Tanboga, I. H. [4 ]
Ozdemir, N. [1 ]
Kaymaz, C. [1 ]
机构：
[1] Kartal Kosuyolu Heart & Res Hosp, Istanbul, Turkiye
[2] Kocaeli City Hosp, Cardiol, Kocaeli, Turkiye
[3] Medipol Univ, Cardiol, Istanbul, Turkiye
[4] Hisar Intercontinental Hosp, Cardiol, Istanbul, Turkiye
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension: insights from a single-centre study
    Tokgoz, H. C.
    Kultursay, B.
    Tanyeri, S.
    Hakgor, A.
    Keskin, B.
    Bulus, C.
    Sekban, A.
    Sirma, D.
    Karagoz, A.
    Tanboga, I. H.
    Ozdemir, N.
    Kaymaz, C.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [2] Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension
    Hu, Xiaoyi
    Yuan, Ping
    Chen, Jun
    Wang, Shang
    Zhao, Hui
    Wei, Yaqin
    Fu, Jiaqi
    Chen, Fadong
    Ruan, Hongyun
    Zhang, Wei
    Zhou, Yanli
    Wang, Qiqi
    Xu, Xiaoling
    Feng, Kefu
    Guo, Jianzhou
    Gong, Sugang
    Zhang, Ruifeng
    Zhao, Qinhua
    Wang, Lan
    CLINICAL CARDIOLOGY, 2024, 47 (02)
  • [3] Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
    Momoi, Mizuki
    Hiraide, Takahiro
    Shinya, Yoshiki
    Momota, Hiromi
    Fukui, Shogo
    Kawakami, Michiyuki
    Itabashi, Yuji
    Fukuda, Keiichi
    Kataoka, Masaharu
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2021, 15
  • [4] Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients
    Cui, Xiaopei
    Lu, Weida
    Zhang, Deyuan
    Qie, Liangyi
    Li, Haijun
    Li, Xiao
    Liu, Hui
    Ji, Qiushang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [5] The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
    Rosenkranz, Stephan
    Channick, Richard
    Chin, Kelly M.
    Jenner, Bartosz
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    McLaughlin, Vallerie V.
    Du Roure, Camille
    Rubin, Lewis J.
    Sitbon, Olivier
    Tapson, Victor
    Lang, Irene M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (01) : 205 - 214
  • [6] Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)
    Channick, Richard
    Chin, Kelly
    Di Scala, Lilla
    Frey, Aline
    Preiss, Ralph
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein Ardeschir
    Hoeper, Marius
    Lang, Irene
    McLaughlin, Vallerie
    Rubin, Lewis
    Simonneau, Gerald
    Sitbon, Olivier
    Tapson, Victor
    CHEST, 2015, 148 (04)
  • [7] Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study
    Zhao, Qin-Hua
    Chen, Jun
    Chen, Fa-Dong
    Ruan, Hong-Yun
    Zhang, Wei
    Zhou, Yan-Li
    Wang, Qi-Qi
    Xu, Xiao-Ling
    Feng, Ke-Fu
    Guo, Jian-Zhou
    Gong, Su-Gang
    Zhang, Rui-Feng
    Wang, Lan
    PULMONARY CIRCULATION, 2024, 14 (01)
  • [8] Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag
    Klose, H.
    Chin, K.
    Ewert, R.
    Gall, H.
    Parambil, J.
    Poch, D.
    Seyfarth, H.
    Axelsen, L.
    Schmitz, S. Hsu
    Stein, C.
    Preston, I.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S490 - S490
  • [9] Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
    J. Gerry Coghlan
    Richard Channick
    Kelly Chin
    Lilla Di Scala
    Nazzareno Galiè
    Hossein-Ardeschir Ghofrani
    Marius M. Hoeper
    Irene M. Lang
    Vallerie McLaughlin
    Ralph Preiss
    Lewis J. Rubin
    Gérald Simonneau
    Olivier Sitbon
    Victor F. Tapson
    Sean Gaine
    American Journal of Cardiovascular Drugs, 2018, 18 : 37 - 47
  • [10] Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
    Coghlan, J. Gerry
    Channick, Richard
    Chin, Kelly
    Di Scala, Lilla
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    Lang, Irene M.
    McLaughlin, Vallerie
    Preiss, Ralph
    Rubin, Lewis J.
    Simonneau, Gerald
    Sitbon, Olivier
    Tapson, Victor F.
    Gaine, Sean
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (01) : 37 - 47
12345